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ABSTRACT 
 
The present study was conducted to evaluate the potency and safety of haemorrhagic septicaemia oil 
adjuvant vaccine in Swiss albino mice via subcutaneous route of inoculation. The vaccine was proved 
successful as it gave 70 to 100% protection in Swiss albino mice. 
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INTRODUCTION 
 
Haemorrhagic septicaemia (HS) is one of the most 
fatal infectious diseases of buffaloes and cattle in Asia 
caused by Pasteurella multocida serotype B: 2 (Carter, 
1955; Heddleston et al., 1972). This disease is kept 
under control mainly by the use of an alum-precipitated 
vaccine, which has been replaced in many countries by 
the haemorrhagic septicaemia oil adjuvanted vaccine 
(HSOAV). The latter can protect cattle and buffaloes 
from the disease more effectively than alum 
precipitated vaccine up to one year (Neramitmansook, 
1993). 
It has been recommended that potency of HSOAV 
should be carried out in cattle and buffaloes 
(Anonymous, 2004). However, it is not always possible 
economically to check each and every batch of vaccine 
in cattle and buffaloes. Therefore, laboratory animals 
like rabbit and mice can be used for potency and safety 
testing of HS vaccines. In the present study, Swiss 
albino mice were used for potency and safety testing of 
HSOAV (Yadev and Ahooja, 1983). The mouse 
provides a good model for HS infection as it manifests 
septicaemic form of disease similar to that observed in 
the natural hosts (Ose and Muenster, 1968; Dawkins et 
al., 1990; Tabatabaei et al., 2002). 
 
MATERIALS AND METHODS 
 
Experimental mice 
For potency testing, protocols of Ose and Muenster 
(1968) and OIE Terrestrial Manual (Anonymous,     
2004)   were   followed. A total of 160 Swiss albino 
mice, about 5-6 weeks old and weighing approximately 
25-30 gms were used.  These mice were divided into 
four groups A, B, C and D, with 40 mice in each group. 
Mice of groups A, B and C were vaccinated with three  
 
different batches of HSOAV prepared at Veterinary 
Research Institute Lahore. Group D animals were kept 
as unvaccinated control. 
 
Vaccination 
Three batches of HSOAV prepared according to 
the standard protocols (Anonymous, 2004) were 
evaluated for potency and safety. All the experimental 
mice in groups A, B and C were vaccinated with 
respective batch @ 0.25 ml (0.37 mg dry bacterial 
weight approximately) subcutaneously. A booster dose 
of 0.25 ml/mice subcutaneously was given after 15 days 
(Gupta and Sareen 1976; Tasneem, 1993). 
 
Lethal dose calculation 
Pasteurella multocida serotype B: 2 was cultured 
in tryptose phosphate broth and LD50 was calculated 
according to Reed and Muench (1938). LD50 of 
challenge was about 10
-5.5, 100 LD50 was 10
-4.5 and 
1000 LD50.was 10
-3.5                                                                                      
 
Challenge 
Fourteen days after booster dose each group was 
further divided into two subgroups (A1, A2, B1, B2, C1 
C2 and D1, D2). Mice of each subgroup were challenged 
with 100 LD50 and 1000 LD50 of challenge inoculums 
@ 0.25 ml/mice subcutaneously and were kept under 
observation for seven days. 
 
RESULTS AND DISCUSSION 
 
The results obtained are summarized in Table 1. 
Mice of Group A1 vaccinated with batch No.1 showed 
100% protection with 100 LD50 and Group A2 mice 
showed 90% protection with 1000 LD50. Mice of groups 
B1  and B2 which were vaccinated with batch No. 2 
showed 90% protection with100 LD50 and 75% with 
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1000 LD50. Similarly, groups C1  and C2  which were 
vaccinated with batch No. 3 showed 90% protection 
with100 LD50 and 80% with 1000 LD50.  All mice of 
group D (D1, D2), which were kept as unvaccinated 
control, died after challenge with 100 LD50 and 1000 
LD50 of challenge culture.  
In this study, albino mice were used for potency 
and safety testing of HSOAV. A similar study was 
conducted by Tasneem (1993), who evaluated potency 
and safety of HSOAV by intraperitoneal route of 
inoculation and observed high protection. In this study, 
subcutaneous route was adopted for vaccination of mice 
instead of deep intramuscular or intra peritoneal 
inoculation. This route was proved to be safe without 
any adverse local reaction at the site of injection as was 
observed in the case of large animals (Anonymous, 
2004).  Time interval of booster and challenge were 
increased so that vaccine can work properly, as in oil 
adjuvant vaccine antigen is slowly released from depot. 
The results showed that HSOAV gave good protection 
level up to 90%, which was higher than recommended 
level to pass a batch of vaccine to be used in field (Ose 
and Muenster, 1968). The results obtained in the 
present study coincide with those of Ose and Muenster 
(1968) and Yadev and Ahooj (1983) that vaccine was 
found safe and potent if it gave 2 log unit protection in 
laboratory animals. 
These results indicate that it is possible to use mice 
successfully for safety and potency testing of HSOAV 
via subcutaneous route. There was no death after 
vaccination and secondly there was no untoward 
reaction in mice up to seven days.  
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